AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Arrowhead Research Corporation
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SGT8G5
58.02▼ 0.34 (-0.58%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
58.36
Day's Range
56.56 – 58.40
52-Week Range
36.73 – 95.49
Volume
860.2K
Avg Volume
2.2M
Share Statistics
Shares Outstanding
Employees
711
Exchange
XNAS
Listed
1995-02-01
Share count as of July 30, 2026

Arrowhead Research Corporation (ARWR) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Arrowhead Research Corporation (ARWR)
What is Arrowhead Research Corporation's Market Cap?
Arrowhead Research Corporation's Market Cap is $8.2B, based on as-reported figures from SEC (XBRL) filings.
What is Arrowhead Research Corporation's Enterprise Value?
Arrowhead Research Corporation's Enterprise Value is $8.3B, based on as-reported figures from SEC (XBRL) filings.
What is Arrowhead Research Corporation's Price / Sales?
Arrowhead Research Corporation's Price / Sales is 12.2×, based on as-reported figures from SEC (XBRL) filings.
What is Arrowhead Research Corporation's EV / Revenue?
Arrowhead Research Corporation's EV / Revenue is 12.4×, based on as-reported figures from SEC (XBRL) filings.
What is Arrowhead Research Corporation's EV / EBITDA?
Arrowhead Research Corporation's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Arrowhead Research Corporation's Revenue (TTM)?
Arrowhead Research Corporation's Revenue (TTM) is $669.5M, based on as-reported figures from SEC (XBRL) filings.
What is Arrowhead Research Corporation's Net Income (TTM)?
Arrowhead Research Corporation's Net Income (TTM) is -$320.0M, based on as-reported figures from SEC (XBRL) filings.
What is Arrowhead Research Corporation's EBITDA?
Arrowhead Research Corporation's EBITDA is -$202.3M, based on as-reported figures from SEC (XBRL) filings.
What is Arrowhead Research Corporation's Diluted EPS (TTM)?
Arrowhead Research Corporation's Diluted EPS (TTM) is -2.27, based on as-reported figures from SEC (XBRL) filings.
What is Arrowhead Research Corporation's EBITDA Margin?
Arrowhead Research Corporation's EBITDA Margin is -30.2%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ARWRAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth+171.0%-86.4%+10461.3%—
Operating expenses:
Research and development
Selling, general and administrative——
Total operating expenses
% of revenue326.0%291.6%84.5%82.8%
Operating (loss) income
% of revenue-226.0%-191.6%15.5%17.2%
Other income (expense):
Interest income
Interest expense
Loss on equity method investment——
Gain on VIE's sale of IPR&D assets——
Other, net
Total other (expense) income
(Loss) income before income tax expense (benefit) and noncontrolling interest
Income tax expense (benefit)
Net (loss) income including noncontrolling interest
% of revenue-237.8%-186.6%10.7%6.3%
Net income (loss) attributable to noncontrolling interest, net of tax
Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.
% of revenue-258.2%-180.0%11.7%-9.3%
Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:
Basic (in dollars per share)
Diluted (in dollars per share)—